127 related articles for article (PubMed ID: 15910556)
1. Upregulation of the immune system in primary hypercholesterolaemia: effect of atorvastatin therapy.
Sampietro T; Bigazzi F; Rossi G; Dal Pino B; Puntoni MR; Sbrana F; Chella E; Bionda A
J Intern Med; 2005 Jun; 257(6):523-30. PubMed ID: 15910556
[TBL] [Abstract][Full Text] [Related]
2. Elevated ICAM-1 and MCP-1 plasma levels in subjects at high cardiovascular risk are diminished by atorvastatin treatment. Atorvastatin on Inflammatory Markers study: a substudy of Achieve Cholesterol Targets Fast with Atorvastatin Stratified Titration.
Blanco-Colio LM; Martín-Ventura JL; de Teresa E; Farsang C; Gaw A; Gensini G; Leiter LA; Langer A; Martineau P; Egido J;
Am Heart J; 2007 May; 153(5):881-8. PubMed ID: 17452168
[TBL] [Abstract][Full Text] [Related]
3. Effects of Atorvastatin on some inflammatory parameters in severe primary hypercholesterolemia.
Dobreanu M; Gălăţeanu C; Simionescu A; Deac R
Rom J Intern Med; 2002; 40(1-4):61-73. PubMed ID: 15526541
[TBL] [Abstract][Full Text] [Related]
4. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance.
Sasaki J; Ikeda Y; Kuribayashi T; Kajiwara K; Biro S; Yamamoto K; Ageta M; Kobori S; Saikawa T; Otonari T; Kono S
Clin Ther; 2008 Jun; 30(6):1089-101. PubMed ID: 18640465
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin treatment decreases inflammatory and proteolytic activity in patients with hypercholesterolemia.
Ercan E; Tengiz I; Altuglu I; Sekuri C; Aliyev E; Ercan HE; Akin M
Kardiol Pol; 2004 May; 60(5):454-8. PubMed ID: 15247960
[TBL] [Abstract][Full Text] [Related]
6. Up regulation of C3, C4, and soluble intercellular adhesion molecule-1 co-expresses with high sensitivity C reactive protein in familial hypoalphalipoproteinaemia: further evidence of inflammatory activation.
Sampietro T; Bigazzi F; Dal Pino B; Rossi G; Chella E; Lusso S; Puntoni M; Tuoni M; Bionda A
Heart; 2004 Dec; 90(12):1438-42. PubMed ID: 15547024
[TBL] [Abstract][Full Text] [Related]
7. Levels of adhesion molecules do not decrease after 3 months of statin therapy in moderate hypercholesterolaemia.
Jilma B; Joukhadar C; Derhaschnig U; Rassoul F; Richter V; Wolzt M; Dorner GT; Petternel V; Wagner OF
Clin Sci (Lond); 2003 Feb; 104(2):189-93. PubMed ID: 12546641
[TBL] [Abstract][Full Text] [Related]
8. Effect of atorvastatin on microRNA 221 / 222 expression in endothelial progenitor cells obtained from patients with coronary artery disease.
Minami Y; Satoh M; Maesawa C; Takahashi Y; Tabuchi T; Itoh T; Nakamura M
Eur J Clin Invest; 2009 May; 39(5):359-67. PubMed ID: 19371267
[TBL] [Abstract][Full Text] [Related]
9. Atorvastatin reduces sympathetic activity and increases baroreceptor reflex sensitivity in patients with hypercholesterolaemia and systemic arterial hypertension.
Siński M; Lewandowski J; Ciarka A; Bidiuk J; Abramczyk P; Dobosiewicz A; Gaciong Z
Kardiol Pol; 2009 Jun; 67(6):613-20. PubMed ID: 19618317
[TBL] [Abstract][Full Text] [Related]
10. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
11. Genetic influence in antithrombotic actions of atorvastatin in hypercholesterolaemia.
Puccetti L; Bruni F; Pasqui AL; Pastorelli M; Ciani F; Palazzuoli A; Acampa M; Auteri A
Eur J Clin Invest; 2008 Jan; 38(1):11-6. PubMed ID: 18173546
[TBL] [Abstract][Full Text] [Related]
12. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
13. The effect of atorvastatin treatment on lipid profile and adhesion molecule levels in hypercholesterolemic patients: relation to low-density lipoprotein receptor gene polymorphism.
Bolewski A; Lipiecki J; Plewa R; Burchardt P; Siminiak T
Cardiology; 2008; 111(2):140-6. PubMed ID: 18376126
[TBL] [Abstract][Full Text] [Related]
14. Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients.
Ando H; Sugimoto K; Yanagihara H; Tsuruoka S; Saito T; Takamura T; Kaneko S; Fujimura A
Clin Exp Pharmacol Physiol; 2008 Sep; 35(9):1012-7. PubMed ID: 18430053
[TBL] [Abstract][Full Text] [Related]
15. Increased levels of pregnancy-associated plasma protein-A in patients with hypercholesterolemia: the effect of atorvastatin treatment.
Stulc T; Malbohan I; Malík J; Fialová L; Soukupová J; Ceska R
Am Heart J; 2003 Dec; 146(6):E21. PubMed ID: 14661010
[TBL] [Abstract][Full Text] [Related]
16. Effects of high-dose atorvastatin on antiinflammatory properties of high density lipoprotein in patients with rheumatoid arthritis: a pilot study.
Charles-Schoeman C; Khanna D; Furst DE; McMahon M; Reddy ST; Fogelman AM; Paulus HE; Park GS; Gong T; Ansell BJ
J Rheumatol; 2007 Jul; 34(7):1459-64. PubMed ID: 17552046
[TBL] [Abstract][Full Text] [Related]
17. Pregnancy-associated plasma protein-A elevation in patients with acute coronary syndrome and subsequent atorvastatin therapy.
Miedema MD; Conover CA; MacDonald H; Harrington SC; Oberg D; Wilson D; Henry TD; Schwartz RS
Am J Cardiol; 2008 Jan; 101(1):35-9. PubMed ID: 18157962
[TBL] [Abstract][Full Text] [Related]
18. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial.
Fraley AE; Schwartz GG; Olsson AG; Kinlay S; Szarek M; Rifai N; Libby P; Ganz P; Witztum JL; Tsimikas S;
J Am Coll Cardiol; 2009 Jun; 53(23):2186-96. PubMed ID: 19497447
[TBL] [Abstract][Full Text] [Related]
19. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial.
Stender S; Schuster H; Barter P; Watkins C; Kallend D;
Diabetes Obes Metab; 2005 Jul; 7(4):430-8. PubMed ID: 15955130
[TBL] [Abstract][Full Text] [Related]
20. Effect of intensive lipid-lowering therapy on telomere erosion in endothelial progenitor cells obtained from patients with coronary artery disease.
Satoh M; Minami Y; Takahashi Y; Tabuchi T; Itoh T; Nakamura M
Clin Sci (Lond); 2009 May; 116(11):827-35. PubMed ID: 19090788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
